4//SEC Filing
Kaye Edward M. MD 4
Accession 0001522780-25-000008
CIK 0001623526other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 8:22 PM ET
Size
14.7 KB
Accession
0001522780-25-000008
Insider Transaction Report
Form 4
Kaye Edward M. MD
Director
Transactions
- Exercise/Conversion
Common Stock
2024-12-01+4,317→ 53,441 total - Sale
Common Stock
2025-12-02$29.56/sh−661$19,540→ 52,780 total - Sale
Common Stock
2025-12-02$30.14/sh−405$12,207→ 52,375 total - Sale
Common Stock
2025-12-03$30.34/sh−419$12,712→ 51,956 total - Sale
Common Stock
2025-12-03$30.85/sh−651$20,082→ 51,305 total - Exercise/Conversion
Restricted Stock Units
2025-12-01−4,317→ 0 totalExp: 2025-12-01→ Common Stock (4,317 underlying)
Footnotes (7)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
- [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F7]21,591 restricted stock units vested on December 1, 2024 and 4,317 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001522780
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 8:22 PM ET
- Size
- 14.7 KB